



Biofit

FOSTERING
INNOVATION
& TRANSFER

A 360° approach to source early-stage
innovations in Life Sciences

AGENDA

6th
edition

& 28th
29th
NOVEMBER
2017



Strasbourg

France



Organised by



With the support of



BIOFIT AT A GLANCE

BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation in the field of Life Sciences. BioFIT is also the marketplace for pre-seed, seed and Series A investment in Life Sciences.



THEY SUPPORT US

SPONSORS



SUPPORTERS



MEDIA PARTNERS



THE ORGANISERS

EURASANTE

Eurasanté is both an incubator, a technology transfer tool, as well as a cluster manager in the fields of biotech, nutrition and healthcare in Northern France. It assists French and foreign companies, entrepreneurs, scientists and clinicians in their innovation and development projects.

The regional network includes around 1,000 organisations working in the field of Life Sciences and Healthcare. It benefits from an exceptional location in the heart of Europe (near Paris, London, Brussels...). The Biology Health Nutrition sector in Hauts-de-France region gathers a total of 28,000 employees, including 22,000 directly involved in the Nutrition / Health sector. Eurasanté also promotes the Eurasanté Bio-business Park which already hosts 7 hospitals, 4 universities, 7 specialised schools, more than 150 companies and 50 laboratories. In addition, Eurasanté organises 4 international partnering events which aim to increase and improve interactions between academia and industry.

www.eurasante.com @Eurasante



THE NHL CLUSTER

The Nutrition Health Longevity (NHL) Cluster is a dynamic network focusing on today's main health issues at the crossroads of health, biotechnology and nutrition.

The NHL Cluster aims to federate public and private partners around R&D projects leading to innovative products in the fields of nutrition and health.

The NHL Cluster focuses on the fields of prevention and treatment of life-style related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its objective is to gather and support players from the health and food sectors in designing, developing and financing products and processes of the future.

www.nhl-cluster.com @PoleNSL



ALSACE BIOVALLEY

As a French world-class cluster dedicated to therapeutic innovations, Alsace BioValley is the one-stop contact to optimise any R&D development or business project in Europe, both in drug development and medical technologies. Located in Eastern France, part of the famous French-German-Swiss BioValley and with a unique concentration of international life sciences & healthcare players, Alsace BioValley helps any Life Sciences & Healthcare companies or academics interested in new projects and partnerships in Europe: To search outstanding scientific or industrial partners to develop very innovative R&D projects, to find the best innovative technology, patent or scientific expertise, or to set up and locate in Eastern France. Alsace BioValley has also agreements with BioWin (Wallonia), CQDM (Quebec), JBA (Japan Bioidustry Association), Biopro (Germany) and Basel Area (Switzerland).

www.alsace-biovalley.com @AlsaceBiovalley



THE STEERING COMMITTEE

PHARMA, BIOTECH



Cédric BARRIERE
DIRECTOR, EXTERNAL INNOVATION
ONCOLOGY, EXTERNAL SCIENCE
AND PARTNERING
SANOFI [FR]



Maria BOBADILLA
SENIOR DIRECTOR, EXTENDING
INNOVATION NETWORK,
ROCHE [CH]



Adrian CARTER
CORPORATE VICE PRESIDENT AND
GLOBAL HEAD OF DISCOVERY
RESEARCH COORDINATION,
BOEHRINGER INGELHEIM [DE]



Sami CHTOUROU
DIRECTOR OF TECHNOLOGY
PLATFORMS AND INNOVATION,
LFB [FR]



Florence DAL DEGAN
R&D INNOVATION SOURCING
DIRECTOR, NOVO NORDISK [DK]



Guy HELIN
CEO, SYNGULON [BE]



Stephan LENSKY
CHIEF OPERATING AND CHIEF
BUSINESS OFFICE, EPIMAB
BIOTHERAPEUTICS [CN]



Sabrina LESAGE
STRATEGIC ALLIANCES MANAGER,
PFIZER [FR]



Pascal RAOUL
SCIENTIFIC AND INNOVATION
DIRECTOR, CEVA [FR]



Frédéric SCAEROU
DIRECTOR, SCIENTIFIC
AFFAIRS ONCOLOGY,
IPSEN INNOVATION [FR]



Nadine WEISSLINGER-DARMON
MEDICAL DIRECTOR SPECIALTY
PRODUCTS, CLINICAL RESEARCH
AND ACADEMIC ALLIANCES
GSK [FR]

ACADEMIA, TTOs



Hervé ANSANAY
OPERATIONS DIRECTOR,
SATT AXLR [FR]



Garold BREIT
DIRECTOR, TECHNOLOGY
BUSINESS DEVELOPMENT,
CITY OF CHARLESTON [USA]



Nicolas CARBONI
PRESIDENT, SATT CONECTUS
ALSACE [FR]



Jean-Luc CHAGNAUD
HEALTHCARE BUSINESS
DEVELOPMENT MANAGER
& INTELLECTUAL PROPERTY
MANAGER, AQUITAINE SCIENCE
TRANSFERT [FR]



Lilla FARKAS
HEAD, OFFICE OF THE
MANAGING DIRECTOR, RESEARCH
COORDINATOR, MPI-CBG,
MAX PLANCK INSTITUTE OF
MOLECULAR CELL BIOLOGY AND
GENETICS [DE]



Matthieu FISICHELLA
LIFE SCIENCES EXPERT,
SATT NORD [FR]



Esther LANGE
INDUSTRY LIAISON MANAGER,
ASCENION [DE]

ASSOCIATIONS, CLUSTERS, INVESTORS & LAW FIRMS



Claude-Alain CU DENNEC
GENERAL DIRECTOR, AFSSI -
THE FRENCH ASSOCIATION
OF OUTSOURCING AND
INNOVATIVE COMPANIES [FR]



Barbara FREISCHEM
MANAGING DIRECTOR, EBE -
EUROPEAN BIOPHARMACEUTICAL
ENTERPRISES [BE]



Jean-Louis HUNAU LT
PRESIDENT, SIMV - THE FRENCH
ASSOCIATION OF THE ANIMAL
HEALTH INDUSTRY [FR]



Marco PINTORE
GENERAL MANAGER,
ALSACE BIOVALLEY [FR]



Christian POLICARD
MEMBER OF THE BOARD,
CHAIRMAN OF THE BUSINESS
DEVELOPMENT SUB-COMMITTEE,
FRANCE BIOTECH [FR]



Sara NUNEZ-GARCIA
PRINCIPAL,
SOFINNOVA PARTNERS [FR]



Emilie ROYERE
DIRECTOR, EUROBIOMED [FR]




Cécile THEARD-JALLU
PARTNER ATTORNEY, DE GAULLE
FLEURANCE & ASSOCIÉS [FR]



Etienne VERVAECKE
GENERAL MANAGER,
EURASANTE & NHL CLUSTER [FR]

PARTNERING

48 hours to meet your future project partners,
accelerate innovation and get financed



Who will you meet?



30% TTOs, Research institutions, Academics



20% Pharma & Diagnostic companies



20% Emerging biotech companies



15% Preclinical CROs



10% Pre-seed, seed and Series A investors



5% Professional services, consulting and law firms

The partnering at BioFIT is powered by **partneringONE™**
A service of **EBDGROUP**

PRESENTATION SESSIONS

The early-stage innovations you need

The BioFIT presentation sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development in the Life Sciences sector.

Start-up Slams

The Start-up Slams are dedicated to **young entrepreneurs** (< 5years) who have created or are about to create an innovative company. The selected applicants will receive **speed-mentoring** from a jury of experts.

Licensing Opportunity Presentations

The Licensing Opportunity Presentations are dedicated to **TTOs, universities** or related structures that have **ready-to-be-licensed technologies**. The aim of this session is to foster alliances and business development opportunities on innovative projects stemming from academia.



Apply



Be selected



Pitch

Deadline to apply: 30th June 2017

CONFERENCE PROGRAMME

Track 1

New players involved in innovation in the health sector

Big data and health IT companies provide key expertise to potentially increase efficiency in the discovery, preclinical and clinical stages of development. What will be their position and involvement in the therapeutic innovation chain: Will they participate or lead? Examples of collaborations between biotech, pharma and academic research will be highlighted. However, these new players don't only originate from the big data sector, they also come from various areas such as animal health or e-health.

Track 2

Nurturing and licensing early-stage assets

Early-stage assets evolve in an ecosystem in which TTOs, scientists and entrepreneurs are closely connected. This subject will focus on assessing opportunities in licensing early-stage projects, discussing the mentoring role of TTOs and exploring the scientists' commitment. It aims to underline the difficulties for maturing early-stage assets. How can we transform science into business more frequently and efficiently?

Track 3

Bioentrepreneurs' challenges at pre-seed, seed and Series A stages

The right mindset, a solid presentation and business model are not the sole requirements that bioentrepreneurs must fulfil at pre-seed, seed and Series A stages. What are the expectations of project maturity from seed investors in 2017? How often are new types of early-stage investors involved in financing rounds (including philanthropic and specialised ventures)? How does the angels/seed investors relationship work? Are there increasing interactions and partnerships between pharma and VCs at these initial stages?

Plenary session

How can we overcome the shortage of bioentrepreneurs in Europe?

Europe is currently benefitting from a unique level of academic research and the access to equity investment has also improved. Despite this, Europe is still lacking bioentrepreneurs. How can we attract entrepreneurs towards Life Sciences? How to convince talented scientists to become entrepreneurs? Can the support from technology transfer offices, incubators and early investors provide sufficient mentorship and a wide enough network?



DAY ONE Tuesday 28th November

	Conferences and roundtable discussions	Presentation sessions	Partnering	Hosted event
8.30 am 9.30 am	REGISTRATION AND WELCOME			
9.30 am 11.00 am	How can collaborations in rare diseases be an asset in a highly competitive yet fast moving market?	Shared risk or competition for emerging assets: How should the pharma-VC relationship function?	Licensing Opportunity Presentations	R&D dating for animal health and innovation
11.00 am 11.30 am	NETWORKING BREAK		One-to-one meetings	BREAK
11.30 am 1.00 pm	PLENARY SESSION: How can we overcome the shortage of bioentrepreneurs in Europe?			
1.00 pm 2.30 pm	LUNCH		One-to-one meetings	LUNCH
2.30 pm 3.00 pm	Crash course: How to value your start-up?			R&D dating for animal health and innovation
3.00 pm 4.30 pm	Exploring the growing relationship between pharma, digital health companies and data providers	Assessing the opportunity in licensing early-stage projects		Start-up Slams
4.30 pm 5.00 pm	NETWORKING BREAK		One-to-one meetings	BREAK
5.00 pm 6.30 pm	Focused therapeutic funds: Is this the new trend in financing early-stage innovation?	Licensing Opportunity Presentations		
7.00 pm	BIOPARTY			

DAY TWO Wednesday 29th November

	Conferences and roundtable discussions	Presentation sessions	Partnering	Hosted event	
8.30 am 9.00 am	REGISTRATION AND WELCOME				
9.00 am 10.30 am	How are collaborations key to improve innovation in metabolic diseases?	How can we encourage the founding scientists to remain committed?	Start-up Slams	R&D dating for animal health and innovation	
10.30 am 11.00 am	NETWORKING BREAK		One-to-one meetings	BREAK	
11.00 am 12.30 pm	How can animal innovation and human applications be mutually beneficial?	Where will European pre-seed, seed and Series A investment go in 2018?		Licensing Opportunity Presentations	R&D dating for animal health and innovation
12.30 pm 2.00 pm	LUNCH			LUNCH	
2.00 pm 3.30 pm	Which role to play for the TTO in the early development of the spin off?		Start-up Slams	R&D dating for animal health and innovation	
3.30 pm 4.30 pm	How can we define a mutually beneficial collaboration between a start-up and the originating academic institution?			R&D dating for animal health and innovation	



BioFIT will host the 3rd edition of the “R&D dating for Animal Health and Innovation”, initiated by the French association for the animal health industry (SIMV) on 28th and 29th November 2017, in Strasbourg.

Today, public-private and private-private partnerships are thought to be the needed leverage for innovation. Hence, the SIMV (the French association for the animal health industry) launched the “R&D dating for Animal Health and Innovation” which aims at initiating high-level exchanges between the research departments of the veterinary medicine and diagnostics industry and public research, as well as biotechnology companies (start-ups).

By enabling face-to-face encounters, the event will enhance the visibility of cutting-edge research in France and in Europe, encourage investments, and lead to therapeutic innovation.

Organised by



Meet & Match

The day before BioFIT, BIOPRO Baden-Württemberg and Alsace BioValley organise a Meet & Match event on the following subject: Strategies for Drug Discovery: simulation – screening – repurposing.

The Meet & Match is a regularly offered full-day event on specific topics aiming at exchanging ideas in small groups of 40 to 80 participants.

Company representatives and project leaders from the health industry (biotech and pharma) as well as academic researchers from both sides of the Rhine - France (Grand Est region) and Germany (Baden-Württemberg) - meet each other to generate new impulses or partnerships for joint developments. Short presentations of about 15-20 minutes on a common topic are given in English, lunch and coffee breaks allow intensive networking and collaborations initiations.

Thus, this event will be a great opportunity for biotech companies, contract research organisations and academic labs to present and envision future approaches, which would match the pharma industry needs.



BioParty

28TH NOVEMBER

Palais de la Musique
et des Congrès

From 7.00 PM



Cocktail



Networking

Dancing



FOLLOW THE RHYTHM AND
ENJOY YOUR NETWORKING EVENING

Free for all BioFIT registrants

REGISTER NOW FOR BIOFIT 2017

REGISTRATION FEES (excl. VAT)

	FULL PRICE
Mature company (> 5 years old).....	€ 1,199
Investor (pre-seed, seed or Series A).....	€ 1,199
Cluster Association.....	€ 1,019
TTO Research institution.....	€ 799
Emerging company (≤ 5 years old) or SME (≤ 5 employees)	€ 479
Academic scientist.....	€ 399

EARLY BIRD before 30th June

€ 959
€ 959
€ 816
€ 639
€ 384
€ 319

EXHIBITION FEES (excl. VAT)

Gain visibility by exhibiting on a fully equipped booth within the exhibition area and hold your one-to-one meetings on your own stand.

Equipped booths:

6 m²



€ 2,200

(1 partnering pass incl.)

9 m²



€ 3,300

(1 partnering pass incl.)

12 m²



€ 4,400

(1 partnering pass incl.)

18 m²



€ 6,600

(2 partnering passes incl.)

SPONSORSHIP OPPORTUNITIES (excl. VAT)

Discover the sponsorship opportunities and maximise your presence:



Gold Sponsor
€ 15,000



Silver Sponsor
€ 9,000



Bronze Sponsor
€ 6,000

There are many additional
visibility opportunities, please
contact us for a tailored offer.



EVENT VENUE

Strasbourg Convention Centre
Palais de la Musique et des Congrès
Place de Bordeaux
67082 Strasbourg - France

www.biofit-event.com



@BIOFIT_EVENT

CONTACTS

GENERAL ENQUIRIES:

Margaux SATOLA
msatola@eurasante.com
+33 (0)3 59 39 01 82

CONFERENCE PROGRAMME:

Claire LESNIK
clesnik@eurasante.com
+33 (0)3 59 39 01 87



STRASBOURG AND THE GRAND EST REGION:

HOTSPOT FOR LIFE SCIENCES INNOVATIONS

The heartbeat of the Rhine basin and the Grand Est region, Strasbourg occupies a strategic position at the crossroads of France, Germany and Switzerland. The region and city's growth is driven by an innovative economy and world class universities which work closely with the industry. Strasbourg is located in the famous French-German-Swiss bioValley, which is host to almost half of the world's leading pharmaceutical companies (Lilly, Sanofi, Novartis...). It is a unique concentration of actors of excellence in Life Sciences and Health. Renowned companies, world-class research institutes and scientific award winners share their expertise in areas such as medical and surgical robotics, minimally invasive surgery, genetics and molecular and cell biology, neuroscience, chemistry or biomaterials. All these players benefit from many advantages of an ecosystem boosted by Alsace BioValley, a world-class cluster which actively supports therapeutic innovation projects, whether they are related to new drugs or medical technologies.



INSTITUTIONAL PARTNERS

